This is one of the more interesting longevity papers I have seen recently. A July 2026 Nature Communications study looked at an engineered enzyme called CMLase. The researchers designed it to target CML, one type of advanced glycation damage that can build up on long lived proteins over time. In isolated tissue, they reported major reductions in CML from collagen, aged human artery, skin, and eye lens samples. The important part is the limitation. This was not a human treatment trial. The work was done outside the body, and we still do not know whether the enzyme could be delivered effectively, whether the immune system would tolerate it, or whether removing CML would actually make tissues function younger. That is what makes this interesting to me. The research challenges the old assumption that this type of accumulated damage has to stay permanent, but there is still a big gap between an exciting laboratory result and something we can actually use in humans. I broke down the study, the measurement differences, the current evidence around glycation, and what we can realistically do today in the full video: https://youtu.be/XsUjonGMqzE?si=v0HQ-WtXUdUp7Et9 Community question: If scientists eventually prove that accumulated glycation damage can be safely removed in humans, where do you think the biggest impact would be: cardiovascular health, skin aging, eyesight, or longevity overall? Drop your take below. I want to hear how everyone here is looking at this research.